Aliskiren in Patients With Idiopathic Membranous Nephropathy

Withdrawn before enrolling · Not applicable

Conditions studied: Idiopathic Membranous Nephropathy

In brief

The goal of this proposal is to conduct a pilot study to access the antiproteinuric effect of aliskiren in patients with idiopathic membranous nephropathy. Patients will be treated for 3 months with aliskiren aiming to achieve the maximum tolerated dose and blood pressure (\>100 but \<125 mmHg systolic BP \>75% of the readings).

Key facts

Study ID
NCT01093781
Run by
Mayo Clinic
People needed
0
Starts
2010-11-01
Expected to finish
2011-12-01
Last updated by the study team
2013-03-13

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.